• Provide Category 1 CME Continuing Education Units (CEU) equivalent to a minimum of 5 CEU credits. OFFEROR may provide a single curriculum or up to two curricula, provided that the total credits available are equivalent to at least 5 CEU credits. • Contain multiple modules addressing topics that include: the endocannabinoid system and phytocannabinoids, indications and contraindications for medical use of cannabis, modes of administration, dosing, and pharmacology of cannabis products (including hemp-derived cannabidiol products), physiologic and cognitive effects, side effects, drug interactions, precautions in patient populations with special conditions, federal and state regulations, scientific developments on potential therapeutics, and a review of medical evidence for and against the use of medical cannabis, including adverse events, cannabis use disorder, psychosis risks, and other public health concerns • Be adapted for Hawaii-licensed medical professionals by including Hawaii laws and regulations, and indications and contraindications for the use of medical cannabis to treat each of Hawaii’s qualifying conditions (https://health.hawaii.gov/medicalcannabisregistry/providers/debilitatingmedical-conditions/ ), and a review of medical evidence for and against the benefits of using medical cannabis to treat each of Hawaii’s qualifying conditions • Incorporate case studies where appropriate • Be evidence-based and unbiased, demonstrated through thorough review of scientific literature • Be delivered through an online audio and video program with an ondemand schedule • Include self-assessment quizzes upon completion of each module and prior to issuing certificate of completion • Issue certificate of completion with trainee’s name and date of completion
